

Dear customers,

as of July 24, 2008, ORPEGEN Pharma GmbH has sold its bio-businesses in an asset deal with Glycotope GmbH, Berlin. From now on, at her permanent location in Heidelberg, ORPEGEN Pharma GmbH focuses fully on the chemical development and production of peptide drug substances according to GMP requirements including the manufacture of amino acid derivatives. We also have enforced our contract GMP work for customers on "Small Molecules".

Based on this core competence, the parent company has established ORPEGEN Peptide Chemicals GmbH, a 100 % daughter corporation, which actively pursues this focussed direction with entire dedication towards our international clientele, grown impressively over the past 26 year on our contract services !

Thanks and best regards !

Your sincerely,

Christian Birr
President & CEO